$MLTX


A rebound path like the one I marked with arrow is possible. The news flow must not deteriorate.
MoonLake made it clear that, after receiving positive feedback from the Type B meeting with the FDA, it can target a sonelokimab BLA submission for HS in 2H26 without doing an additional HS study. This news brought the BLA timing forward but did not guarantee final FDA approval.
post-image
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin